Focus on sibutramine: A new anorectic agent for the treatment of obesity

Formulary

Volumn 32, Issue 10, 1997, Pages 1025-1039

  Luque, Carla A ^a,b   Rey, Jose A ^a,c   Fernandez, Antonio ^d,e  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d Internal Medicine Residency Program   (United States)

^e UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIGENIC AGENT; DEXFENFLURAMINE; FENFLURAMINE; NEW DRUG; NORADRENALIN UPTAKE INHIBITOR; PHENTERMINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SIBUTRAMINE;

BEHAVIOR MODIFICATION; CLINICAL TRIAL; CONSTIPATION; DIET THERAPY; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG POTENCY; FOOD AND DRUG ADMINISTRATION; HUMAN; INSOMNIA; OBESITY; ORAL DRUG ADMINISTRATION; PULMONARY HYPERTENSION; REVIEW; SATIETY; WEIGHT REDUCTION; XEROSTOMIA;

EID: 0030723324     PISSN: 00986909     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Weiser M, Frishman W, Michaelson MD, Abdeen MA. The pharmacologic approach to the treatment of obesity. J Clin Pharmacol 1997;37:453-73.
2. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults. JAMA 1994;272:205-11.
3. Silverstone T. Appetite suppressants: A review. Drugs 1992;43:820-36.
4. McCann UD, Seiden LS, Rubin LJ, Ricaurte GA. Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine: A systematic review of the evidence. JAMA 1997;278:666-72.
5. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581-8.
6. Cannistra L. Valvular heart disease associated with dexfenfluramine. N Engl J Med 1997;337:636.
7. Food and Drug Administration-Endocrinologic and Metabolic Drugs Advisory Committee Meeting Proceedings. Sept 26, 1996.
8. Buckett WR, Thomas PC, Luscombe GP. The pharmacology of sibutramine hydrochloride (BTS 54524), a new antidepressant which induces rapid noradrenergic down-regulation. Prog Neuropsychopharmacol Biol Psychiatry 1988;12:575-84.
9. Anon. Sibutramine. Drugs Fut 1995;20: 847-8.
10. King DJ, DeVaney N. Clinical pharmacology of sibutramine hydrochloride (BTS 54524), a new antidepressant, in healthy volunteers. Br J Clin Pharmacol 1988;26:607-11.
11. Luscombe GP, Slater NA, Lyons MB, et al. Effect on radiolabelled-monoamine uptake in vitro of plasma taken from healthy volunteers administered the antidepressant sibutramine HCl. Psychopharmacology 1990;100:345-9.
12. Stock MJ. Sibutramine: A review of the pharmacology of a novel anti-obesity agent. Int J Obes 1997;21(Suppl 1):S25-S29.
13. 3H]noradrenaline uptake and effect of DSP-4 lesioning and antidepressant treatments. Neuropharmacology 1996;35:63-70.
14. 3H]5-HT uptake: Effect of administration of various antidepressant treatments. Neuropharmacology 1993;32:737-43.
15. Heal DJ, Frankland ATJ, Gosden J, et al. A comparison of the effects of sibutramine hydrochloride, bupropion and methamphetamine on dopaminergic function: Evidence that dopamine is not a pharmacological target for sibutramine. Psychopharmacology 1992;107:303-9.
16. 2 antagonists, but not by sibutramine hydrochloride, antidepressants or treatments which enhance central dopaminergic function. J Neural Transm 1995;102:35-46.
17. Fantino M, Souquet AM. Effects of metabolites 1 and 2 of sibutramine on the short-term control of food intake in the rat (abstract). Int J Obes 1995; 19(Suppl 2):145.
18. Halford JCG, Heal DJ, Blundell JE. Effects in the rat of sibutramine on food intake and the behavioural satiety sequence (abstract). Br J Pharmacol 1995;114:387P.
19. Connoley IP, Frost I, Heal DJ, Stock MJ. Role of β-adrenoceptors in mediating the thermogenic effects of sibutramine (abstract). Br J Pharmacol 1996;117(Suppl):170P.
20. Liu YL, Kashani SMZ, Heal DJ, Stock MJ. Effect of sibutramine on tissue glucose utilization in the rat (abstract). Br J Pharmacol 1996;117(Suppl):324P.
21. Griffiths J, et al. Sibutramine in the treatment of overweight non-insulin dependent diabetics (abstract). Int J Obes 1995;19(Suppl 2):41.
22. Shepherd G, Fitchet M, Kelly F. Sibutramine: A meta-analysis of the change in fasting plasma glucose in patients with a high baseline fasting value (abstract). Int J Obes 1997;21(Suppl 2):S54.
23. Fitchet M, Shepherd G, Kelly F. Sibutramine: A meta-analysis of changes in fasting serum lipids in placebo controlled studies (abstract). Int J Obes 1997;21(Suppl 2):S53.
24. Oya M, Dominguez R, Heath M. The effect of sibutramine induced weight loss in obese subjects with hyperlipidemia (abstract). Int J Obes 1997;21(Suppl 2):S54.
25. Weintraub M, Rubio A, Golik A, et al. Sibutramine in weight control: A dose-ranging, efficacy study. Clin Pharmacol Ther 1991;50:330-7.
26. Jones SP, Newman BM, Romance FM. Sibutramine hydrochloride: Weight loss in overweight subjects (abstract). Int J Obes 1994;18(Suppl 2):61.
27. Bray GA, Blackburn GL, Ferguson JM, et al. Sibutramine: Dose response and long-term efficacy in weight loss. A double-blind study (abstract). Int J Obes 1994;18(Suppl 2):60.
28. Mendels J, Blackburn GL, Bray GA, et al. Sibutramine and long-term weight loss: Percentage of patients losing 5% and 10% of baseline weight (abstract). Int J Obes 1994;18(Suppl 2):60.
29. Bray GA, Ryan DH, Gordon D, et al. A double-blind randomized placebo-controlled trial of sibutramine. Obes Res 1996;4:263-70.
30. Jones SP, Smith IG, Kelly F, Gray JA. Long-term weight loss with sibutramine (abstract). Int J Obes 1995;19 (Suppl 2):41.
31. Jones SP, Heath MJ. Long term weight loss with sibutramine: 5% responders (abstract). Int J Obes 1996;20(Suppl 4):157.
32. Kelly F, Wade AG, Jones SP, Johnson SG. Sibutramine hydrochloride vs dexfenfluramine: Weight loss in obese subjects (abstract). Int J Obes 1994; 18(Suppl 2):61.
33. Drouin P, Hanotin C, Thomas F, et al. Efficacy and tolerability of sibutramine versus dexfenfluramine in obese patients (abstract). Int J Obes 1995;19(Suppl 2):144.
34. Hazenberg BP, Johnson SG, Kelly F. Sibutramine in the treatment of obese subjects with hypertension (abstract). Int J Obes 1996;20(Suppl 4):156.
35. Lean MEJ. Sibutramine-A review of clinical efficacy. Int J Obes 1997;21 (Suppl 1):S30-36.
36. Gosden J, Buckett WR, Heal DJ. d-Amphetamine-cued drug discrimination in rats: Predictive value for detecting stimulant drugs of abuse (abstract). Br J Pharmacol 1996;117:169P.
37. Cole JO, Friedman L, Kaiser PE, de Haan HA. Sibutramine hydrochloride: Evaluation of abuse potential. Psychopharm Bull 1995;31:557.